C-Reactive Protein (CRP) Medium and Severe Symptoms Levels of COVID-19

Manalu, Erida and Suryana, Adelia Winanda and Luhulima, Danny Ernest Jonas (2022) C-Reactive Protein (CRP) Medium and Severe Symptoms Levels of COVID-19. Journal of Drug Delivery and Therapeutics (JDDT), 12 (6). pp. 152-156. ISSN 2250 1177

	Text CReactiveProteinMediumandSevere.pdf Download (549kB)
	Text (Hasil_Turnitin) TurnitinCReactiveProteinMediumandSevere.pdf Download (1MB)

Abstract

Coronavirus Disease 2019 (COVID-19) is a disease caused by SARS-CoV-2 and has caused a global pandemic. Patients with COVID-19 can experience symptoms such as fever, dry cough, headache, and shortness of breath which can lead to pneumonia. Excessive inflammation is considered a leading cause of critical illness and death in COVID-19 patients. C-Reactive Protein is a sensitive indicator as an early marker of infection and inflammation. This study presents an overview of the difference in the average CRP levels between patients with moderate and severe confirmed COVID-19 symptoms at UKI Hospital for June-September 2021. The study design was cross-sectional with descriptive and analytical data presentation obtained from medical record documents at UKI Hospital. The average CRP level of COVID-19 patients with moderate symptoms is 63,705 mg/L, totaling 139 patients. The average CRP level of COVID-19 patients with severe symptoms is 132,050 mg/L, totaling 57 patients. The results obtained from the Mann-Whitney test between groups of patients with moderate and severe COVID-19 showed a significant difference between CRP levels with moderate and severe symptoms with p <0.05.Keywords: COVID-19, CRP levels, SARS-CoV-2

Actions (login required)

View Item